Haemonetics (NYSE:HAE – Get Free Report)‘s stock had its “buy” rating reiterated by investment analysts at BTIG Research in a research note issued on Friday,Benzinga reports. They currently have a $84.00 target price on the medical instruments supplier’s stock. BTIG Research’s target price points to a potential upside of 8.98% from the stock’s previous close.
Several other equities research analysts also recently weighed in on the company. Mizuho increased their price target on Haemonetics from $70.00 to $85.00 and gave the stock an “outperform” rating in a research report on Monday, June 15th. Robert W. Baird set a $67.00 price objective on Haemonetics in a report on Friday, May 8th. Bank of America upgraded Haemonetics from a “neutral” rating to a “buy” rating and upped their target price for the stock from $72.00 to $80.00 in a research note on Friday, May 22nd. Wall Street Zen raised Haemonetics from a “hold” rating to a “buy” rating in a report on Saturday, May 23rd. Finally, Weiss Ratings downgraded Haemonetics from a “hold (c-)” rating to a “sell (d+)” rating in a report on Thursday, May 21st. One analyst has rated the stock with a Strong Buy rating, six have issued a Buy rating, three have given a Hold rating and one has assigned a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $78.33.
Get Our Latest Analysis on HAE
Haemonetics Price Performance
Haemonetics (NYSE:HAE – Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The medical instruments supplier reported $1.29 earnings per share for the quarter, topping analysts’ consensus estimates of $1.28 by $0.01. Haemonetics had a net margin of 7.29% and a return on equity of 27.30%. The firm had revenue of $346.35 million for the quarter, compared to analyst estimates of $336.83 million. During the same quarter in the prior year, the business earned $1.24 earnings per share. The business’s quarterly revenue was up 4.8% compared to the same quarter last year. Haemonetics has set its FY 2027 guidance at 5.258-5.307 EPS. On average, sell-side analysts forecast that Haemonetics will post 5.22 EPS for the current year.
Hedge Funds Weigh In On Haemonetics
Institutional investors and hedge funds have recently modified their holdings of the business. Kemnay Advisory Services Inc. acquired a new position in Haemonetics in the 4th quarter worth about $26,000. True Wealth Design LLC increased its position in shares of Haemonetics by 6,700.0% in the fourth quarter. True Wealth Design LLC now owns 340 shares of the medical instruments supplier’s stock valued at $27,000 after buying an additional 335 shares in the last quarter. Leonteq Securities AG acquired a new position in shares of Haemonetics during the 4th quarter worth approximately $30,000. EverSource Wealth Advisors LLC lifted its position in shares of Haemonetics by 2,640.0% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 411 shares of the medical instruments supplier’s stock valued at $31,000 after buying an additional 396 shares in the last quarter. Finally, Kestra Advisory Services LLC purchased a new position in shares of Haemonetics during the 4th quarter valued at approximately $34,000. Hedge funds and other institutional investors own 99.67% of the company’s stock.
About Haemonetics
Haemonetics Corporation is a global provider of blood management solutions that support the collection, processing and transfusion of blood and blood products. The company’s offerings are designed to enhance patient safety and operational efficiency for blood centers, hospitals and plasma collection facilities. Haemonetics serves healthcare providers worldwide by delivering integrated systems, software and consumables that address critical needs throughout the continuum of blood management.
The company’s product portfolio includes automated apheresis and plasma collection systems, surgical blood salvage and coagulation monitoring devices, and pathogen reduction technologies.
Further Reading
- Five stocks we like better than Haemonetics
- This Single Factor Is Holding Back Carvana’s Disruptive Edge
- BlackBerry’s Rally Is Running on a Bigger AI Story Than Earnings Alone
- MDA Space Targets US Defense Market With $620M Acquisition
- Carnival’s Second Quarter: Is the Stock Still Complicated?
Receive News & Ratings for Haemonetics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Haemonetics and related companies with MarketBeat.com's FREE daily email newsletter.
